Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

(20S) -Protopanaxatriol

Catalog No: tcsc2999

Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Specifications

CAS No:
34080-08-5

Formula:
$C_{30}H_{52}O_4$

Pathway:
Others;GPCR/G Protein;Metabolic Enzyme/Protease

Target:
Estrogen Receptor/ERR;Glucocorticoid Receptor;LXR

Purity / Grade:
>98%

Solubility:
DMSO : ≥ 47 mg/mL (98.59 mM)

Alternative Names:
20(S)-APPT;g-PPT

Observed Molecular Weight:
476.73

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Product Description

(20S)-Protopanaxatriol is a metabolite of ginsenoside, works through the **glucocorticoid receptor (GR)** and **oestrogen receptor (ER)**, and is also a **LXRα** inhibitor.

IC50 & Target: Glucocorticoid receptor, Oestrogen receptor[1], LXRα[2]

In Vitro: (20S)-Protopanaxatriol works through the glucocorticoid receptor (GR) and oestrogen receptor (ER) in human umbilical vein endothelial cells (HUVECs). (20S)-Protopanaxatriol (g-PPT) increases $[Ca^{2+}]_i$ with an EC_{50} of 482 nM in HUVECs. (20S)-Protopanaxatriol (1 μM) elevates NO production via ERβ[1]. (20S)-Protopanaxatriol (PPT) inhibits the autonomous transactivation of Gal4-LXRα LBD, the T0901317-dependent transcription of SREBP-1c and its promoter. (20S)-Protopanaxatriol (10 μg/mL) blocks the recruitment of RNA polymerase II to the LXRE region of SREBP-1c. (20S)-Protopanaxatriol also inhibits T0901317-dependent transcription of LXRα target genes related to lipogenesis, and reduces T0901317-induced cellular triglyceride (TG) accumulation in primary hepatocytes, but does not alter transcription of ABCA1, also an LXRα target gene[2].